Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1722875

	registered interest
	date	23/07/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has made representations to the National Institute for Health and Care Excellence on the availability of Enhertu for patients with HER2-low breast cancer.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	1334
	answer	answer is ministerial correction date of answer 19/08/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations on whether new medicines should be routinely funded by the National Health Service in England independently on the basis of the available evidence of costs and benefits and through engagement with the NHS, manufacturers, patient groups and other interested parties.</p><p>The Department regularly meets with colleagues in NICE to discuss a range of issues, including Enhertu for patients with HER2-low breast cancer. However, the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 provide that Ministers must not direct NICE as to the substance of its recommendations. These are very difficult decisions to make. NICE recognises that its decisions have important implications for patients and their families and only publishes final guidance on the use of a drug after a very careful consideration of the evidence and extensive engagement with interested parties including patients and clinicians. Therefore, it would not be appropriate for Ministers to intervene.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 19/08/2024 11:15:39 answering member 4444 label Biography information for Karin Smyth previous answer version 1723 answering member constituency Bristol South answering member printed Karin Smyth answering member 4444 label Biography information for Karin Smyth
	tabling member	4623 label Biography information for Tonia Antoniazzi

1722876

	registered interest
	date	23/07/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has had discussions with his counterparts in (a) Scotland, (b) Wales and (c) Northern Ireland on access to Enhertu for patients with HER2-low breast cancer.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	1335
	answer	answer is ministerial correction date of answer 19/08/2024 answer text <p>My Rt hon. Friend, the Secretary of State for Health and Social Care, spoke with his counterparts in Scotland and Wales on his first full day in office and will continue to engage with them on a regular basis. However decisions on the availability of individual treatments to National Health Service patients in Wales, Scotland and Northern Ireland are for the devolved administrations so he has therefore had no discussions about the availability of Enhertu for HER2-low breast cancer with his counterparts.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 19/08/2024 11:18:10 answering member 4444 label Biography information for Karin Smyth previous answer version 1722 answering member constituency Bristol South answering member printed Karin Smyth answering member 4444 label Biography information for Karin Smyth
	tabling member	4623 label Biography information for Tonia Antoniazzi

1702287

	registered interest
	date	18/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breastfeeding
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential impact of increased rates of breastfeeding on cost savings for the NHS.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	22611
	answer	answer is ministerial correction date of answer 25/04/2024 answer text <p>The public health benefits of breastfeeding for child and maternal health are significant and well established. Research published in the British Medical Journal suggests that increasing breastfeeding rates, both in terms of duration and exclusivity, is likely to generate substantial cost savings to the National Health Service, although the actual amounts saved will depend on the extent of this increase.</p><p>Through the Family Hubs and Start for Life Programme, we are investing £50 million to increase the range of specialist support, which is enabling more parents to access face-to-face and virtual support whenever they need it. One of the objectives of the programme is to improve the evidence base around the impact of breastfeeding interventions, and the specific combination of interventions that are effective in different circumstances. This is expected to strengthen the case for further, more widespread investment in the future.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 25/04/2024 11:32:06 answering member 4117 label Biography information for Andrea Leadsom
	tabling member	4623 label Biography information for Tonia Antoniazzi

1689180

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Shortages
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what comparative assessment she has made of trends in the total number of medicine shortages recorded by her Department in January (a) 2021, (b) 2022, (c) 2023 and (d) 2024.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	14113
	answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>There are around 14,000 licensed medicines, and the overwhelming majority are in good supply. However, the medicine supply chain is highly regulated, complex and global, and supply disruption is a common issue which affects countries all around the world.</p><p>The Department’s medicine Discontinuations and Shortages portal has been collecting notifications from suppliers of potential supply issues since October 2020, and shows that there were approximately:</p><p>- 90 supply issue notifications in January 2021;</p><p>- 110 supply issue notifications in January 2022;</p><p>- 170 supply issue notifications in January 2023; and</p><p>- 160 supply issue notifications in January 2024.</p><p>Although reporting does vary each month, annual notifications have remained fairly stable at approximately 1,600 supply issue notifications in 2022 and 2023. It is important to note that not all supply issue notifications will lead to a medicine shortage.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/02/2024 11:24:53 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4623 label Biography information for Tonia Antoniazzi

1689181

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Parkinson's Disease: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with the Medicines and Healthcare products Regulatory Agency on the average licensing approval decision timelines for (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	14114
	answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.</p><p>We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14115 question first answered 27/02/2024 11:32:52 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4623 label Biography information for Tonia Antoniazzi

1689182

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Parkinson's Disease: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps with the Medicines and Healthcare products Regulatory Agency to reduce the time taken to license (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	14115
	answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.</p><p>We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 14114 question first answered 27/02/2024 11:32:52 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4623 label Biography information for Tonia Antoniazzi

1685842

	registered interest
	date	30/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Shortages
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to tackle medicine shortages.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	12074
	answer	answer is ministerial correction date of answer 05/02/2024 answer text <p>There are around 14,000 licensed medicines and the overwhelming majority are in good supply. However, the medicine supply chain is highly regulated, complex, and global, meaning there can sometimes be supply issues which affect the United Kingdom, along with other countries around the world.</p><p>Medicine supply problems can occur for several reasons such as manufacturing difficulties, regulatory non-compliance, access to raw materials, sudden demand spikes or distribution issues.</p><p>While it is not always possible to prevent supply issues from occurring, there is a team within the Department that has a range of well-established tools and processes to manage them when they arise, working closely with the pharmaceutical industry, the National Health Service, the Medicines and Healthcare products Regulatory Agency and others operating in the supply chain to help mitigate the risks to patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 05/02/2024 15:39:06 answering member 4044 label Biography information for Andrew Stephenson previous answer version 15319 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4623 label Biography information for Tonia Antoniazzi

1683706

	registered interest
	date	19/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescriptions: Fees and Charges
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the list of medical conditions which meet the criteria for a medical exemption certificate.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	10653
	answer	answer is ministerial correction date of answer 26/01/2024 answer text <p>Approximately 89% of prescriptions are dispensed free of charge. People on a low income who do not qualify for an exemption from prescription charges can seek help under the NHS Low Income Scheme, which provides help with health costs on an income-related basis. For those who do not qualify for an exemption, prescription prepayment certificates (PPCs) allow people to obtain as many prescriptions as they need for a set cost. A three-monthly PPC or an annual PPC will save people money if they need four or more items in three months or <ins class="ministerial">12</ins> <del class="ministerial">13</del> or more items in 12 months.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 26/01/2024 09:57:19 question first ministerially corrected 01/02/2024 15:51:08 answering member 4117 label Biography information for Andrea Leadsom previous answer version 13571 answering member constituency South Northamptonshire answering member printed Andrea Leadsom answering member 4117 label Biography information for Andrea Leadsom
	tabling member	4623 label Biography information for Tonia Antoniazzi

1606002

	registered interest
	date	21/03/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Databases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure data held on the proposed NHS Federated Data Platform is protected.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	170685
	answer	answer is ministerial correction date of answer 30/03/2023 answer text <p>Data processes and systems within the Federated Data Platform (FDP) will need to comply with the Technology Code of Practice, Government Digital Service standards, the Department’s guide to good practice for digital and data-driven health technologies, the Data Protection Act 2018 and the United Kingdom’s General Data Protection Regulation, Information Commissioner’s Office guidance and associated regulations, standards and guidance.</p><p> </p><p>To ensure that the FDP complies, the data sharing approach will consist of: a Data Protection Impact Assessment (DPIA) for the procurement of the FDP solution; overarching DPIA to articulate the data security and protection principles and lawful bases for deployment; purpose-specific DPIAs, which will be drafted for each use case and will go through the formal approval routes within NHS England prior to roll-out; and a legal mechanism for the sharing and processing of data, to be agreed in consultation with NHS England Information Governance and legal counsel.</p><p /><p>The above activities will be concurrent and aligned with the procurement process to ensure data protection by design and default principles are embedded, and there is co-production of the final data sharing approach.  This will ensure that the lawful basis for the data sharing is identified, and Common Law Duty of Confidentiality is adhered to for all of the use cases.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 171540 question first answered 30/03/2023 15:12:24 answering member 4423 label Biography information for Will Quince
	tabling member	4623 label Biography information for Tonia Antoniazzi

1586651

	registered interest
	date	17/02/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Cygnet Healthcare
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the average daily cost to the NHS was for a person receiving mental health support in a hospital ward owned by Cygnet Health Care in the latest period for which data is available.
	tabling member constituency	Gower
	tabling member printed	Tonia Antoniazzi
	uin	147363
	answer	answer is ministerial correction date of answer 22/02/2023 answer text <p>The information requested is not held centrally.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 22/02/2023 16:50:48 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4623 label Biography information for Tonia Antoniazzi